The total return over the past 12 months is -21.73% vs. +16.94% for the S&P 500. So far it's up -39.44% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | (21.73%) | +28.00% | (12.01%) | (16.62%) | N/A | N/A |
| Total Return CAGR | (21.73%) | +28.00% | (12.01%) | (16.62%) | N/A | N/A |
| Revenue CAGR | (87.03%) | (38.70%) | +2.18% | +7.07% | N/A | N/A |
| Net Income CAGR | (266.00%) | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | (178.10%) | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
CytomX Therapeutics, Inc. (CTMX)
| Year | Start price | End price | CTMX Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $4.26 | $2.58 | (39.44%) | +14.51% | (53.95%) |
| 2025 | $1.03 | $4.26 | +313.59% | +17.72% | +295.87% |
| 2024 | $1.55 | $1.03 | (33.55%) | +24.89% | (58.44%) |
| 2023 | $1.60 | $1.55 | (3.13%) | +26.19% | (29.32%) |
| 2022 | $4.33 | $1.60 | (63.05%) | (18.17%) | (44.88%) |
| 2021 | $6.55 | $4.33 | (33.89%) | +28.74% | (62.63%) |
| 2020 | $8.31 | $6.55 | (21.18%) | +18.37% | (39.55%) |
| 2019 | $15.10 | $8.31 | (44.97%) | +31.22% | (76.19%) |
| 2018 | $21.11 | $15.10 | (28.47%) | (4.56%) | (23.91%) |
| 2017 | $10.99 | $21.11 | +92.08% | +21.70% | +70.38% |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
